毓美人再获国际HPV大会认可 精选HPV科研报告

第33届国际HPV大会(国际人乳头瘤病毒学会)在西班牙巴塞罗那举行,毓美人独创分子靶向多重抗病毒技术再次受到国际HPV大会的邀请出席,再一次向全球证明了毓美人私护产品的先进技术与毓美人私护产品研发团队的水平。

毓美人再获国际HPV大会认可 精选HPV科研报告

毓美人

毓美人独创分子靶向多重抗病毒技术,通过富含的灵芝多糖靶向包裹,破坏HPV、HSV病毒DNA,阻断病毒与受体结合,同时双向调节,提升细胞免疫力,从根本上起到清除病毒的作用。自2010年起毓美人产品技术已经是连续多次受到国际HPV大会主办方邀请参会,多次荣登国际舞台,今年再一次证明了毓美人产品的核心技术水平在HPV科研领域的地位!

据毓美人了解,国际HPV大会创立以来,每年都会在中国、美国、德国等不同国家举办,来自世界各地的代表参会,国内外知名院士、教授和专家进行专题演讲,对当前人乳头瘤病毒(HPV)领域最新的基础研究、流行病学、药物临床研究、诊断、防治研究和医学经济学等方面进行深入而全面的探讨。

那么在本届国际HPV大会上又发表了哪些科研报告呢?毓美人精选了第33届国际HPV大会的第二天,大会发表的《Development of
Spontaneous Hpv-16 E6/E7-Expressing Cervicovaginal Preclinical Model that
Follows Clinical Tumor Progression Via Integration of HPV Oncogenes (ID
277)》自然表达HPV-16 E6/E7的子宫颈阴道临床前模型的建立,通过HPV致癌基因整合来跟踪临床肿瘤进展的报告内容:

TALIA R. HENKLE (United States of America)

Introduction

A suitable preclinical HPV tumor model should possess the following
characteristics:(1)forms spontaneous, localized, HPV-16 E6/E7-expressing
tumor,(2)displays carcinoma morphology,(3)possesses locally immunosuppressive
tumor microenvironment, resembling that of HPV16(+) tumors in patients,(4)tumor
formation follows clinical progression starting from precancerous to cancerous
state,(5)tumor- bearing mice can respond appropriately to immunotherapeutic
strategies and generate antitumor immunity, and (6)tumorigenesis can be easily
monitored.

Methods

To this end, we recently developed a method to induce the spontaneous
formation of HPV-16 E6/E7-expressing tumors in the cervicovaginal tracts of
C57BL/6 mice by transiently depleting systemic T cells and submucosally
injecting plasmids encoding HPV16 E6/E7, luciferase, constitutively active
AKT,c-Myc, and Sleeping Beauty transposase into the cervicovaginal area of
mice,followed by electroporation. Tumor formation was closely monitoried by
bioluminescence imaging and gene expressions were characterized by
immunohistochemical staining and RNA in situ hybridization.

Results

Formation of luciferase-expressing tumor in the cervicovaginal tract of
injected mice occurred in 80-100% of animals by week 5 after
electroporation(Figure 1). Remarkably, histologic progression from precancerous
lesions(squamous intraepitheliual lesions) to invasive squamous cell carcinoma
resembled cancer progression of HPV-associated malignancies in human patients
(Figure 2). Furthermore, the expression of transfected oncogenes and HPV E6/E7
oncogenes was demonstrated in the tumor (Figure 3).

毓美人再获国际HPV大会认可 精选HPV科研报告

Figure 2. Progression of lesion from LSIL>HSIL SCC in spontaneous HPV+
cervicovaginal carcinoma model. At each timepoint corresponding with the
indicated luminescence value, 3 mice were sacrificed and their reproductive
tract was harvested for sectioning (A) Representative images of vaginal tissue
with ~105 luminescence signal at 1 week post-electroporation exhibiting low
grade squamous intraepithelial lesion ( LSIL )[see box]. (B) Representative
images of vaginal tissue with ~10 luminescence signal at 2 weeks post
electroporation exhibiting high grade squamous intraepithelial lesion(HSIL). (C)
Representative images of vaginal tissue with ~107 luminescence signal at 3 weeks
post -electroporation exhibiting HSIL and invasive carcinoma [see box]. (D)
Representative images of tumor tissue with ~108 luminescence signal at 4 weeks
post-electroporation. Tumor presents as elldifferentiated SCC with presence of
keratin pearls [see box]

Conclusions

This new preclinical tumor model has potential utility for the preclinical
evaluation of treatments for precancerous lesions, and offers several advantages
as preclinical model for HPV-associated malignancies for the evaluation of novel
cancer treatments and immunotherapies compared to transplantable tumor models
and transgenic mouse models such as the ability to extend to the creation of
tumor model generated by different high risk types of HPV, the lack of central
immune tolerance for HPV E6/E7 oncogenic proteins and the application to mice
with different MHC class genetic background.

简介

一个合适的临床前HPV肿瘤模型应具有以下特点: (1)形成自然的、局部的、表达HPV-16
E6/E7的肿瘤;(2)显示肿瘤的形态;(3)具有类似HPV16(+)肿瘤患者那样的局部免疫抑制的肿瘤微环境;(4)肿瘤的形成遵循从癌前病变到癌变的临床进程;(5)荷瘤小鼠能够对免疫治疗策略做出适当的反应并产生抗肿瘤免疫;
(6)肿瘤的发生过程易于监测。

方法

为此,我们最近开发了一种方法,通过在小鼠子宫颈阴道部位瞬时耗尽免疫系统T细胞和黏膜下注射编码HPV16 E6/E7、荧光素酶、激活型AKT、c-Myc、
睡美人转座子的表达质粒,然后进行电穿孔,来诱导C57BL/6小鼠子官颈阴道部位形成自然表达HPV-16
E6/E7肿瘤。生物发光成像密切监控肿瘤的形成,免疫组织化学染色和RNA原位杂交检测基因表达。

结果

在电穿孔后的第5周,有80-100%的注射小鼠在子宫颈阴道部位形成了荧光素酶表达的肿瘤(图1)。
值得注意的是,从癌前病变(鳞状上皮内病变)到鳞状细胞浸润癌的组织学进展与人类乳头状瘤病毒相关恶性肿瘤的进展相似(图2)。此外,肿瘤中显示了转染致癌基因和HPVE6/E7致癌基因的表达(图3)。

结论

这种新的临床前肿瘤模型对于癌前病变治疗的临床前评估具有潜在的实用价值,与可移植肿瘤模型和转基因小鼠模型相比,作为HPV相关恶性肿瘤的临床前模型在评估新的癌症治疗和免疫疗法方面具有以下优势,例如能够扩展到由不同高危类型的HPV生成的肿瘤模型的创建,对HPVE6/E7致癌基因蛋白缺乏中枢免疫耐受性及其在不同MHC类别遗传背景小鼠中的应用。

版权声明:热玛吉 发表于 2020-07-29 0:00:00。
转载请注明:毓美人再获国际HPV大会认可 精选HPV科研报告 | 301医美导航

暂无评论

暂无评论...